SwiftX™ cfDNA (RUO) - 50 extractions
€641.00
In stock
SKU
XPD-SXCF-50
Kit of reagents for rapid viral cell-free DNA extraction (Buffer CFB, Buffer CFW, Buffer CFE, Beads C)
Catalog Number: XPD-SXCF-50
Size: 50 extractions
More Information
Questions?
All prices without logistics costs.
Catalog Number: XPD-SXCF-50
Size: 50 extractions
More Information
Questions?
All prices without logistics costs.
Rapid & reliable cfDNA extraction in just minutes
Extract cell-free DNA from large volumes of serum, plasma and urine samples in under 15 minutes – faster and more accurate than traditional silica-based extraction methods.
Accuracy you can trust. Speed you need.
SwiftX™ cfDNA offers highly sensitive extraction for liquid biopsy samples, ensuring faster turnaround for cancer detection and prenatal testing. Our protocol outperforms silica-based extraction methods, and is fully compatible with qPCR, ddPCR, and NGS for downstream analysis.
Cell-free DNA extraction for Schistosoma diagnostics
Development of rapid, field-friendly method for isolation of cfDNA from plasma and serum for diagnosis of Schistosoma infections.
E. Gijka et al (2024) poster at the conference of American SOciety of Tropical Medicine and Health, New Orelans, USA.
Read More
Designed for prenatal testing, oncology and infectious disease research
SwiftX™ cfDNA allows you to enhance your oncology research, prenatal testing a.ka. NIPT, and infectious disease studies with high quality cfDNA and reduces your extraction time to under 15 minutes from large sample volumes starting from 0.5mL to 10mL and more – improving efficiency without compromising accuracy. Currently SwiftX cfDNA is not intended for clinical diagnosis but empowers researchers, routine laboratories and oncology assay providers to speed up their workflow and extraction process.
Collaborate with us for cancer research, prenatal and infectious disease testing
Join us in advancing diagnostics with SwiftX™ cfDNA for a range of cancer types and infectious diseases. We’re seeking partners to validate SwiftX cfDNA for range of diseases, oncology screening and pathogen detection such as parasites, mycobacterium and prenatal screening a.k.a NIPT. Partner with us to shape the future of rapid disease detection in both developed countries and Low-and Middle-Income Countries (LMIC).
Contact us?
Extract cell-free DNA from large volumes of serum, plasma and urine samples in under 15 minutes – faster and more accurate than traditional silica-based extraction methods.
Accuracy you can trust. Speed you need.
SwiftX™ cfDNA offers highly sensitive extraction for liquid biopsy samples, ensuring faster turnaround for cancer detection and prenatal testing. Our protocol outperforms silica-based extraction methods, and is fully compatible with qPCR, ddPCR, and NGS for downstream analysis.
Cell-free DNA extraction for Schistosoma diagnostics
Development of rapid, field-friendly method for isolation of cfDNA from plasma and serum for diagnosis of Schistosoma infections.
E. Gijka et al (2024) poster at the conference of American SOciety of Tropical Medicine and Health, New Orelans, USA.
Read More
Designed for prenatal testing, oncology and infectious disease research
SwiftX™ cfDNA allows you to enhance your oncology research, prenatal testing a.ka. NIPT, and infectious disease studies with high quality cfDNA and reduces your extraction time to under 15 minutes from large sample volumes starting from 0.5mL to 10mL and more – improving efficiency without compromising accuracy. Currently SwiftX cfDNA is not intended for clinical diagnosis but empowers researchers, routine laboratories and oncology assay providers to speed up their workflow and extraction process.
Collaborate with us for cancer research, prenatal and infectious disease testing
Join us in advancing diagnostics with SwiftX™ cfDNA for a range of cancer types and infectious diseases. We’re seeking partners to validate SwiftX cfDNA for range of diseases, oncology screening and pathogen detection such as parasites, mycobacterium and prenatal screening a.k.a NIPT. Partner with us to shape the future of rapid disease detection in both developed countries and Low-and Middle-Income Countries (LMIC).
Contact us?
| Is Featured? | No |
|---|
Write Your Own Review